EGFR and neoplasm: Tumor tissue genotyping revealed a median of 10 mutations per patient, with KEAP1 being the most affected gene (81% of patients), followed by TP53 (67%), EGFR, and PDGFRA (52%, Fig. 1B, Table S4).